With regard to atrial fibrillation, Liryc's clinicians have identified the sources of these uncontrolled contractions in the pulmonary veins.
However, the cellular mechanism responsible in the pulmonary veins and the potential molecular targets are still unknown.
Curative treatment has been developed: cauterising the pulmonary veins with a radiofrequency catheter to isolate these sources of arrhythmia. However, progress is still necessary to improve the screening, diagnosis, prognosis and treatment of this arrhythmia:
- to develop better ablation devices for safer, faster and easier procedures,
- to develop specific drug therapies targeting the venous cells,
- to develop biomarkers as well as new strategies.
So, research projects are focused on these challenges.